The Montpellier-based biotech stock falls 3.55% to €23.94 at mid-session, after gaining 5.51% the previous day. The movement occurs in a sluggish Paris market, with the CAC 40 down 1.08% at the same time. However, the stock still maintains a year-over-year gain of 59.28%.
After Wednesday's rebound to €24.12, MedInCell gives back some of the ground gained. The stock is trading in the upper part of its Bollinger Bands (boundaries at €21.31 and €25.35), without approaching them. The price remains slightly above the MM50 at €22.93 and just below the MM200 at €24.03, which has been a pivot for several sessions. The RSI at 49 indicates a neutral momentum, consistent with a nearly unchanged weekly variation (-0.58%). Over three months, performance remains positive at 3.73%, despite a series of volatile sessions since mid-April. The identified support threshold at €20.24 remains distant from the current price. The nearest resistance is at €25.12, a level approached during the peak on April 15 at €24.60.
A Biotech with No Corporate News in a Tense Market
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
No publications or analyst recommendations accompany the session for the Montpellier company. The next financial calendar event is the announcement of the annual results for the fiscal year 2025-2026, scheduled for June 16, 2026. The general assembly is planned for September 10 thereafter. The decline is part of a deteriorating European environment: the SBF 120 is down 0.97% and the DAX 0.26%, while Asian markets closed lower, with the Nikkei 225 losing 1.06% and the Hang Seng 1.27%. Among European biotech comparables, argenx is up 0.18% while Abivax is down 1.02%. A beta of 0.19 confirms the stock's historically low sensitivity to indices, making today's drop more related to the stock's technical breathing than to the general movement. The one-year performance of 59.28% remains a fundamental benchmark, pending the annual publication in June.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
